Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Kawasaki Disease Spread May be Linked to Wind

Richard Quinn  |  Issue: October 2014  |  October 1, 2014

Blowing in the wind

A new study links the spread of Kawasaki disease (KD) in the Far East and the Western U.S. to winds from farmland in northeast China. And the lead author says that rheumatologists studying other rheumatic diseases may want to view the wind as a potential factor in their spread.

The Basics

KD is an acute febrile illness of unknown etiology that primarily affects children younger than 5 years old.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

KD “is characterized by fever, rash, swelling of the hands and feet, irritation and redness of the whites of the eyes, swollen lymph glands in the neck, and irritation and inflammation of the mouth, lips, and throat. Serious complications include coronary artery dilatations and aneurysms. The standard treatment with intravenous immunoglobulin and aspirin substantially decreases the development of these coronary artery abnormalities.”

KD occurs worldwide, with the highest incidence in Japan. It most often affects boys and younger children.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Cultivated fields in northeast China.
Pictured: Cultivated fields in northeast China.

The Study

The new study offers “a different way to look at these sorts of diseases,” says author Xavier Rodó, PhD, an ecologist and climate scientist at the Catalan Institute of Climate Sciences (IC3) in Barcelona, Spain.

Dr. Rodó’s study, “Tropospheric winds from northeastern China carry the etiologic agent of Kawasaki disease from its source to Japan,” was published online this spring by the Proceedings of the National Academy of Sciences.2 It reported that evidence indicates the “densely cultivated region of northeastern China acts as a source for the wind-borne agent” of KD.

“We’re not saying that the KD agent worldwide comes from this region, but that this is the case for Japan and the U.S.,” Dr. Rodó says.

KD is the leading cause of acquired heart disease in children worldwide and causes inflammation, conjunctivitis and other maladies. But little is known of the disease’s background. It primarily affects children younger than age 5 and was first reported in 1967 in Japan. The first reported cases outside of Japan were in Hawaii in 1976, according to the Centers for Disease Control and Prevention.1

Highlighting the importance to rheumatologists, a panel discussion at the 2013 ACR/ARHP Annual Meeting, titled, Kawasaki Disease: Putting Out the Fire, noted the need for early detection of the disease. One of the experts said it’s estimated that one in 1,600 adults in the U.S. will have had KD by 2030.3

Dr. Rodó notes that it’s important for rheumatologists and other physicians to realize the study does not identify KD’s etiologic agent. It also does not confirm whether the agent is a fungus, toxin or another kind of environmental particle.

Page: 1 2 | Single Page
Share: 

Filed under:Career DevelopmentConditionsEducation & TrainingOther Rheumatic ConditionsProfessional Topics Tagged with:ACR/ARHP Annual MeetingChinaJapanKawasaki diseasemicrobeQuinnrheumatologist

Related Articles

    Thinking Big, Thinking Small

    June 17, 2019

    I would like to tell you a story. Two, actually. I am just returning from the 19th International Vasculitis and ANCA Workshop, which is always a fascinating meeting. In its inception, it was a workshop, in the true sense of the word. Now, we discuss anti-neutrophil cytoplasmic antibody (ANCA) testing as casually as we discuss…

    Dr. Kawasaki

    Tomisaku Kawasaki, Pediatrician Who Discovered Disease That Bears His Name, Dies at 95

    June 18, 2020

    Japanese pediatrician Tomisaku Kawasaki, MD, who identified an inflammatory syndrome that affects children, died on June 5 in Tokyo. He was 95. Tenacity & Attention to Detail Born Feb. 7, 1925, in Tokyo, Dr. Kawasaki graduated from medical school at what is now Chiba University in Chiba, Japan, in 1948 and worked as staff pediatrician…

    Exploring Kawasaki Disease

    April 2, 2014

    New epidemiologic data, clinical studies have shed light on diagnosis, treatments, patient outcomes for this childhood disease, but etiology is still unknown

    MIA Studio / shutterstock.com

    Kawasaki Guideline Urges Treatment Intensification for Some Patients

    December 16, 2021

    A soon-to-be published guideline from the ACR and the Vasculitis Foundation on Kawasaki disease underscores the importance of early diagnosis and intensified treatment for people with this serious condition.1 Intravenous immunoglobulin (IVIG) remains the treatment mainstay, and prompt, aggressive treatment may be able to reduce the risk of serious complications in some patients. The guideline…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences